The development of a liquid suspension form of delavirdine (Rescriptor) had disappointing results in one study. Most children rejected the liquid due to its bad taste and were switched to crushed or dissolved tablets, with anti-HIV properties similar to those seen in adult trials.1


  1. Willoughby R et al. Phase I / II evaluation of delavirdine in HIV-1-infected pediatric patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract 1995, 1999